<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242515</url>
  </required_header>
  <id_info>
    <org_study_id>TP02/28/04</org_study_id>
    <nct_id>NCT00242515</nct_id>
  </id_info>
  <brief_title>T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      This a pilot project to determine the feasibility of the preemptive CD8+ depleted T-cell&#xD;
      donor lymphocyte infusion (DLI) in:&#xD;
&#xD;
        -  Reducing the incidence of graft versus host disease (GVHD) based on standard&#xD;
           classification of acute and chronic GVHD&#xD;
&#xD;
        -  Improving hte disease remission rate in comparison with our previous study results.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To investigate the impact of CD8+ depleted T-cell DLI in hematopoietic chimerism, and&#xD;
           immunologic recovery of transplant patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The scientific investigation in this study protocol:&#xD;
&#xD;
        1. Define the role of preemptive and specific DLI in preserving the GVL effect in the&#xD;
           setting of NMT. The ability of selecting components of T cells for transplant and DLI&#xD;
           will allow us to test the hypothesis of distinctive roles in subsets of T cells. It was&#xD;
           found that CD8-depleted DLI was administered to prevent relapse after TCD (T-cell&#xD;
           depleted) BMT (bone marrow as the stem cell source) or CD34-selected PBSC.&#xD;
&#xD;
           Whether preemptive CD8-depleted DLI can perform this function after nonmyeloablative&#xD;
           transplantation (NMT) needs to be established, as proposed in our study. If there turns&#xD;
           out to be a role for DLI in these circumstances, a CD8-depleted lymphocyte product that&#xD;
           can limit GVHD would be a very attractive option. We would also define the relationship&#xD;
           of the level of donor chimerism and disease control.&#xD;
&#xD;
        2. Investigate the impact of CD8-depleted DLI in NMT at specific doses and time points for&#xD;
           the reduction of GVHD. The GVHD pattern may vary between different ethnic populations as&#xD;
           suggested by our earlier NMT study. Our current proposed study will further shed light&#xD;
           on the optimal GVHD prophylaxis regimen in the Singapore patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date>March 2008</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of acute and chronic GVHD</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease remission rate post CD8+ depleted T-cell DLI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic chimerism and immunologic recovery post CD8+ depleted T-cell DLI</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CD8+ T-cell depleted donor lymphocyte infusion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of AML or high risk MDS in the following disease stages: Induction&#xD;
             failure, first or subsequent remission, or untreated first relapse.&#xD;
&#xD;
          2. Patient must have an HLA-compatible donor willing and capable of donating peripheral&#xD;
             blood stem cells preferably or bone marrow progenitor cells using conventional&#xD;
             techniques, and lymphocytes if indicated (HLA-compatible defined as 5/6 or 6/6 matched&#xD;
             related or 6/6 molecular matched unrelated donor)&#xD;
&#xD;
          3. Both patient and donor must sign written informed consent forms.&#xD;
&#xD;
          4. Patients must have:&#xD;
&#xD;
               -  ECOG PS &lt;/= 2;&#xD;
&#xD;
               -  Ejective fraction &gt; 40%;&#xD;
&#xD;
               -  DLCO &gt; 40% of predicted;&#xD;
&#xD;
               -  Serum bilirubin &lt;/= 1.5x institutional upper limit of normal;&#xD;
&#xD;
               -  SGPT (ALT) and SGOT (AST) &lt;/= 2.5x institutional upper limit of normal;&#xD;
&#xD;
               -  Serum creatinine &lt;/= 2x upper limit of normal;&#xD;
&#xD;
               -  Creatinine clearance &gt;/= 60mL/min. However, renal dysfunction is not an absolute&#xD;
                  contraindication for NMT as dialysis can be performed during NMT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not fulfilling any of the inclusion criteria&#xD;
&#xD;
          2. Active life-threatening infection&#xD;
&#xD;
          3. Overt untreated infection&#xD;
&#xD;
          4. HIV positivity, hepatitis B or C antigen positivity with active hepatitis&#xD;
&#xD;
          5. Pregnant or lactating women&#xD;
&#xD;
          6. Donor contraindication (HIV seropositive confirmed by Western blot; hepatitis B&#xD;
             antigenemia)&#xD;
&#xD;
          7. Unable to donate bone marrow or peripheral blood due to concurrent medical condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chien-Shing Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital/National University Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chien-Shing Chen, MD</last_name>
    <phone>67724613</phone>
    <email>mdcccs@nus.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology-Oncology, National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>October 19, 2005</study_first_submitted>
  <study_first_submitted_qc>October 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High risk Myelodysplastic Syndrome (MDS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

